@article{JTD24178,
author = {Angela Botticella and Dirk De Ruysscher},
title = {Lung-sparing intensity-modulated radiotherapy in malignant pleural mesothelioma: palliative or potentially radical?},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 33},
year = {2018},
keywords = {},
abstract = {Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour and its prognosis is dismal. The ASCO and the ESMO guidelines both place a platinum-pemetrexed (or raltitrexed)-based chemotherapy for 4 to 6 cycles as standard of care in fit patients (1,2). However, the median overall survival (OS) is only approximately 12 months, with hardly any 5-year survivors (2).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/24178}
}